Joyce University Expands Nursing Education to Students in Michigan and Kentucky
SALT LAKE CITY--(BUSINESS WIRE)--Aspiring nurses in Michigan and Kentucky can now prepare for RN licensure in as few as 20 months. Joyce University of Nursing and Health Sciences announced today it is broadening its hybrid pre- and post-licensure nursing programs to serve students in both states, furthering its mission to provide accessible, high-quality nursing education nationwide.
Over the past three years, Joyce University has steadily expanded beyond Utah, now serving students in 12 states, with Michigan and Kentucky as its newest additions in 2025. This continued growth underscores the university's commitment to meeting the increasing demand for skilled nurses by offering flexible, career-focused educational pathways tailored to diverse student needs.
'Joyce University is a community committed to improving access to high-quality education for aspiring nurses,' said Josh Knotts, interim President and CEO. 'Our vision is to create transformative learning environments that prepare graduates to make a positive impact on their communities. We are thrilled to bring this commitment and vision to students in Michigan and Kentucky.'
With this expansion, students in Michigan and Kentucky can access a range of pre-licensure programs, such as the 20-month Associate of Science in Nursing (ASN), the 3-year Bachelor of Science in Nursing (BSN), and the accelerated Bachelor of Science in Nursing (aBSN). Joyce University offers two post-licensure programs for those looking to further their nursing careers: the 4-semester online RN to BSN program and the 3-semester online MSN in Leadership program.
Joyce University's hybrid educational model blends online learning with immersive hands-on skill development at the Joyce Johnson Center of Simulation in Draper, Utah. Clinical placements are conducted locally within Michigan and Kentucky, providing practical experience within local communities.
Enrollment for Michigan and Kentucky students is now open, with the next cohort beginning in the Fall Semester on September 2, 2025.
For more information about Joyce University programs or employment opportunities, visit joyce.edu.
ABOUT JOYCE UNIVERSITY
Founded in 1979, Joyce University of Nursing and Health Sciences' mission is to prepare students to serve as competent professionals, to advance their careers, and to pursue lifelong learning. Located in Draper, Utah, Joyce University is proud to have helped thousands of students across the US graduate and launch lasting healthcare careers. With a recent expansion of its pre-licensure programs to select regional locations, including Arizona, Colorado, Idaho, Kentucky, Michigan, Missouri, Nevada, New Mexico, Ohio, Oregon, South Carolina, and Wisconsin, Joyce University's expansion enables aspiring nurses in these regions to access the same high-quality education and opportunities that have defined the institution for decades. Join them as they continue to shape the future of healthcare, one student at a time.
Joyce University is institutionally accredited by the Northwest Commission on Colleges and Universities (NWCCU) and programmatically accredited by the Accreditation Commission for Education in Nursing (ACEN) for the Associate of Science in Nursing degree program and by the Commission on Collegiate Nursing Education (CCNE) for the Bachelor of Science in Nursing and Master of Science in Nursing degree programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company's presentation is scheduled for . Upcoming presentation at BIO 2025 follows successful Series B funding round and encouraging data from ongoing trials The presentation will highlight Azafaros' progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros' recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating nizubaglustat in patients with GM2 gangliosidosis and NPC. The current Ph2 extension study demonstrated a favorable safety profile after more than 12 months of treatment. In addition, preliminary improvements or stabilization in key clinical endpoints were observed in the majority of patients, underscoring promising efficacy trends for nizubaglustat. 'We are excited to share our latest progress at BIO 2025, including the continued clinical development of nizubaglustat which holds strong potential as a meaningful treatment option for patients with devastating neurodegenerative lysosomal disorders,' said Stefano Portolano, CEO at Azafaros. 'With the support of our recent financing round and encouraging data from our ongoing trials, we can continue our rapid momentum to bring this product into pivotal clinical studies as we work to develop a potential new solution for this area where there is a significant unmet need.' About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Paediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Yahoo
7 hours ago
- Yahoo
Nurses to vote on pay deal as potential strike looms
Almost 350,000 nursing staff in England, Wales and Northern Ireland will be asked to vote from Monday on a 3.6% pay increase. The Royal College of Nursing (RCN) has already dismissed the award as "grotesque" and says the vote will be crucial in determining the next steps which could include a ballot for strike action. A bitter pay dispute saw nurses striking in England, Wales and Northern Ireland from late 2022 and through the winter. Some members of other health unions also staged walkouts over pay. With the possibility of another round of industrial action looming, the vote is being billed as the biggest single vote by the profession ever launched in the UK. Ministers in England, Wales and Northern Ireland all announced pay awards following review body recommendations. There was a 5.4% average increase for resident doctors, formally known as junior doctors, 4% for consultants and other senior doctors, and 3.6% for nurses and other health workers. RCN General Secretary Professor Nicola Ranger said that the government had "once again put nursing at the back of the queue when it comes to pay". "Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards." According to the Ranger, nursing staff in England have endured "over a decade of pay erosion", which has resulted in "skyrocketing" numbers of nurses quitting. "It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough," Ranger will say. Resident doctors in England are already being balloted on strike action over pay. Other health unions are organising votes on the pay awards. All this may cast a shadow over a government 10-year plan for the NHS in England due in the next few weeks. The Scottish government has already agreed a two-year 8% pay offer with health unions.
Yahoo
7 hours ago
- Yahoo
Nurses to vote on pay deal as potential strike looms
Almost 350,000 nursing staff in England, Wales and Northern Ireland will be asked to vote from Monday on a 3.6% pay increase. The Royal College of Nursing (RCN) has already dismissed the award as "grotesque" and says the vote will be crucial in determining the next steps which could include a ballot for strike action. A bitter pay dispute saw nurses striking in England, Wales and Northern Ireland from late 2022 and through the winter. Some members of other health unions also staged walkouts over pay. With the possibility of another round of industrial action looming, the vote is being billed as the biggest single vote by the profession ever launched in the UK. Ministers in England, Wales and Northern Ireland all announced pay awards following review body recommendations. There was a 5.4% average increase for resident doctors, formally known as junior doctors, 4% for consultants and other senior doctors, and 3.6% for nurses and other health workers. RCN General Secretary Professor Nicola Ranger said that the government had "once again put nursing at the back of the queue when it comes to pay". "Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards." According to the Ranger, nursing staff in England have endured "over a decade of pay erosion", which has resulted in "skyrocketing" numbers of nurses quitting. "It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough," Ranger will say. Resident doctors in England are already being balloted on strike action over pay. Other health unions are organising votes on the pay awards. All this may cast a shadow over a government 10-year plan for the NHS in England due in the next few weeks. The Scottish government has already agreed a two-year 8% pay offer with health unions.
